title: Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma.
abstract: Bazex syndrome, a rare paraneoplastic syndrome characterized by psoriasiform eruptions, palmoplantar keratosis, and symmetric onychodystrophy, is most prevalent with squamous cell carcinomas of the upper aerodigestive tract.Here, we reported an uncommon case of Bazex syndrome about an 83-year-old man with pulmonary adenocarcinoma and osseous metastasis, Physical examination found psoriasiform eruptions on the nose, cheeks, ears, knees, and the dorsa of interphalangeal joints, along with plantar keratosis and symmetric onychodystrophy involving hands and feet. Imaging analyses pulmonary adenocarcinoma with both local metastatic nodules and osseous metastasis.Symptomatic treatment with topical corticosteroids and oral retinoids showed no improvement. A 4-month follow-up showed that Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, successfully reduced primary tumor size and alleviated cutaneous lesions.Our report here highlighted a potential correlation between pulmonary adenocarcinoma and Bazex syndrome, which is characterized by hallmark nail destruction and preferential involvement of body extremities. Moreover, etiological therapy against underlying malignancy is essential for treating paraneoplastic Bazex syndrome.
authors.affiliation: From the Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Xilin
authors.initials: X
authors.lastname: Zhang
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Chen
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Wu
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D000077192:Adenocarcinoma of Lung; D000369:Aged, 80 and over; D001707:Biopsy, Needle; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D002280:Basal Cell Carcinoma / Q000175:diagnosis* / Q000188:drug therapy; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D007039:Hypotrichosis / Q000175:diagnosis* / Q000188:drug therapy; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy; D011799:Quinazolines / Q000627:therapeutic use; D011859:Radiography; D035583:Rare Diseases; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D011799:Quinazolines; D003907:Dexamethasone; D017255:Acitretin; D000077156:Gefitinib